| Na+/K+-ATPase, its endogenous ligands and neurotransmitter release ES Vizi, F Oberfrank Neurochemistry international 20 (1), 11-17, 1992 | 40 | 1992 |
| Characterization of somatodendritic neuronal nicotinic receptors on the myenteric plexus A Töröcsik, F Oberfrank, H Sershen, Á Lajtha, K Nemesy, ES Vizi European journal of pharmacology 202 (3), 297-302, 1991 | 38 | 1991 |
| Linking individual patient data to estimate incidence and prevalence of Parkinson's disease by comparing reports of neurological services and pharmacy prescription refills at a … S Szatmári Jr, A Ajtay, M Bálint, A Takáts, F Oberfrank, D Bereczki Frontiers in Neurology 10, 640, 2019 | 19 | 2019 |
| Incidence and prevalence of multiple sclerosis in Hungary based on record linkage of nationwide multiple healthcare administrative data A Iljicsov, D Milanovich, A Ajtay, F Oberfrank, M Bálint, B Dobi, D Bereczki, ... PLoS One 15 (7), e0236432, 2020 | 17 | 2020 |
| Noradrenaline releasing effect of an ouabain-like compound on pulmonary artery ES Vizi, F Oberfrank, S Bernath, D Lichtstein Neuropharmacology 26 (10), 1541-1544, 1987 | 15 | 1987 |
| Demand for neurological services in Central Eastern Europe: a 10‐year national survey in Hungary F Oberfrank, A Ajtay, D Bereczki European Journal of Neurology 25 (7), 984-990, 2018 | 13 | 2018 |
| The prevalence of psychiatric symptoms before the diagnosis of Parkinson’s disease in a nationwide cohort: A comparison to patients with cerebral infarction S Szatmári Jr, A Ajtay, F Oberfrank, B Dobi, D Bereczki PLoS One 15 (8), e0236728, 2020 | 12 | 2020 |
| Applicability of hospital reports submitted for reimbursement purposes for epidemiological studies based on the example of ischemic cerebrovascular diseases A Ajtay, F Oberfrank, D Bereczki Orvosi Hetilap 156 (38), 1540-1546, 2015 | 12 | 2015 |
| Socioeconomic gap between neighborhoods of Budapest: Striking impact on stroke and possible explanations I Szőcs, D Bereczki, A Ajtay, F Oberfrank, I Vastagh PLoS One 14 (2), e0212519, 2019 | 8 | 2019 |
| The role of the national health insurance fund administration in the development of health economics and health technology assessment in Hungary F Oberfrank Value in Health Regional Issues 4, 6-7, 2014 | 8 | 2014 |
| The Budapest meeting 2005 intensified networking on ethics of science: the case of reproductive cloning, germline gene therapy and human dignity G Van Steendam, A Dinnyés, J Mallet, R Meloni, CR Casabona, ... Science and engineering ethics 12, 731-793, 2006 | 8 | 2006 |
| Comparison of the effects of a bufodienolide and ouabain on neuronal and smooth muscle preparations F Oberfrank, ES Vizi, PF Baker, S Samuelov, D Lichtstein Neuroscience research 10 (4), 235-244, 1991 | 8 | 1991 |
| Dementia epidemiology in Hungary based on data from neurological and psychiatric specialty services N Balázs, A Ajtay, F Oberfrank, D Bereczki, T Kovács Scientific Reports 11 (1), 10333, 2021 | 7 | 2021 |
| Az aranyművesség története F Oberfrank Műszaki Könyvkiadó, 1996 | 7 | 1996 |
| A kórházi adatlapok jelentéseinek alkalmazhatósága epidemiológiai elemzésekre az ischaemiás cerebrovascularis betegségek példája alapján A Ajtay, F Oberfrank, D Bereczki Orvosi Hetilap 156 (38), 1540-1546, 2015 | 6 | 2015 |
| The Budapest meeting 2005 intensified networking on ethics of science G Steendam, A Dinnyés, J Mallet, R Meloni, CR Casabona, JG González, ... Science and Engineering Ethics 4 (12), 731-793, 2006 | 4 | 2006 |
| Cholinesterase inhibitors for the treatment of dementia: Real-life data in Hungary N Balázs, D Bereczki, A Ajtay, F Oberfrank, T Kovács Geroscience 44 (1), 253-263, 2022 | 3 | 2022 |
| Health insurance cost of stroke in hungary: a cost of illness study F Oberfrank, É Donka-Verebes Value in Health 19 (7), A649, 2016 | 3 | 2016 |
| Assessment of annual health insurance reimbursement for oncology drugs in Hungary I Boncz, F Oberfrank, M Kásler Magyar Onkologia 54 (4), 283-288, 2010 | 3 | 2010 |
| Az onkológiai gyógyszerekre fordított éves egészségbiztosítási kiadások meghatározása Magyarországon I Boncz, É Donkáné Verebes, F Oberfrank, M Kásler Magyar Onkológia 54 (4), 283-288, 2010 | 3 | 2010 |
E. Sylvester Vizi MD, PhD, MHAS, Ho...Institute of Experimental Medicine, and Semmelweis University, Department of Pharmacology andVerified email at koki.hu
